Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 248

Similar articles for PubMed (Select 21241733)

1.

Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda.

Tate JE, Kisakye A, Mugyenyi P, Kizza D, Odiit A, Braka F.

Vaccine. 2011 Apr 12;29(17):3329-34. doi: 10.1016/j.vaccine.2010.12.122. Epub 2011 Jan 15.

PMID:
21241733
2.

Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China.

Liu N, Yen C, Fang ZY, Tate JE, Jiang B, Parashar UD, Zeng G, Duan ZJ.

Vaccine. 2012 Nov 6;30(48):6940-5. doi: 10.1016/j.vaccine.2012.05.084. Epub 2012 Jun 15.

PMID:
22705174
3.

Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.

Fischer TK, Anh DD, Antil L, Cat ND, Kilgore PE, Thiem VD, Rheingans R, Tho le H, Glass RI, Bresee JS.

J Infect Dis. 2005 Nov 15;192(10):1720-6. Epub 2005 Oct 14.

4.

Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.

Flem ET, Latipov R, Nurmatov ZS, Xue Y, Kasymbekova KT, Rheingans RD.

J Infect Dis. 2009 Nov 1;200 Suppl 1:S195-202. doi: 10.1086/605040.

5.

Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.

Tu HA, Rozenbaum MH, Coyte PC, Li SC, Woerdenbag HJ, Postma MJ.

Vaccine. 2012 Feb 14;30(8):1521-8. doi: 10.1016/j.vaccine.2011.11.052. Epub 2011 Nov 23.

PMID:
22119590
6.

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

Asensi F, De Jose M, Lorente M, Moraga F, Ciuryla V, Arikian S, Casciano R, Vento M.

Value Health. 2004 Jan-Feb;7(1):36-51.

PMID:
14720129
7.

Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.

Atherly DE, Lewis KD, Tate J, Parashar UD, Rheingans RD.

Vaccine. 2012 Apr 27;30 Suppl 1:A7-14. doi: 10.1016/j.vaccine.2011.12.096.

PMID:
22520139
8.
9.

Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.

Standaert B, Parez N, Tehard B, Colin X, Detournay B.

Appl Health Econ Health Policy. 2008;6(4):199-216. doi: 10.2165/00148365-200806040-00003.

PMID:
19382820
10.

Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.

Valencia-Mendoza A, Bertozzi SM, Gutierrez JP, Itzler R.

BMC Infect Dis. 2008 Jul 29;8:103. doi: 10.1186/1471-2334-8-103.

11.

Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination.

Shim E, Galvani AP.

Vaccine. 2009 Jun 19;27(30):4025-30. doi: 10.1016/j.vaccine.2009.04.030. Epub 2009 May 3.

PMID:
19389452
12.

Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.

Patel HD, Roberts ET, Constenla DO.

Vaccine. 2013 Dec 9;31(51):6072-8. doi: 10.1016/j.vaccine.2013.10.022. Epub 2013 Oct 29.

13.

Cost-effectiveness of rotavirus vaccination programs in Taiwan.

Chang WC, Yen C, Chi CL, Wu FT, Huang YC, Lin JS, Huang FC, Tate JE, Wu HS, Hsiung CA.

Vaccine. 2013 Nov 4;31(46):5458-65. doi: 10.1016/j.vaccine.2013.08.103. Epub 2013 Sep 20.

PMID:
24060569
14.

Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.

Giglio ND, Cane AD, Micone P, Gentile A.

Vaccine. 2010 Mar 8;28(11):2302-10. doi: 10.1016/j.vaccine.2009.12.070. Epub 2010 Jan 9.

PMID:
20064478
15.

Projected cost-effectiveness of rotavirus vaccination for children in Asia.

Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R.

J Infect Dis. 2005 Sep 1;192 Suppl 1:S133-45.

16.

An economic analysis of rotavirus vaccination in Italy.

Giammanco MD, Coniglio MA, Pignato S, Giammanco G.

Vaccine. 2009 Jun 12;27(29):3904-11. doi: 10.1016/j.vaccine.2009.04.002. Epub 2009 Apr 24.

PMID:
19446934
17.

The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.

Atkins KE, Shim E, Carroll S, Quilici S, Galvani AP.

Vaccine. 2012 Nov 6;30(48):6766-76. doi: 10.1016/j.vaccine.2012.09.025. Epub 2012 Sep 21.

PMID:
23000223
18.

Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

Bos JM, Rümke HC, Welte R, Spanjaard L, van Alphen L, Postma MJ.

Pharmacoeconomics. 2006;24(2):141-53.

PMID:
16460135
19.

Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina.

Urueña A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, Jimenez SG, Jáuregui B, Clark AD, Diosque M, Vizzotti C.

Vaccine. 2011 Jul 12;29(31):4963-72. doi: 10.1016/j.vaccine.2011.04.111. Epub 2011 May 27.

PMID:
21621575
20.

Projected impact and cost-effectiveness of a rotavirus vaccination program in India, 2008.

Esposito DH, Tate JE, Kang G, Parashar UD.

Clin Infect Dis. 2011 Jan 15;52(2):171-7. doi: 10.1093/cid/ciq094.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk